Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Shattuck Labs, Inc. - Common Stock
(NQ:
STTK
)
3.590
+0.100 (+2.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Shattuck Labs, Inc. - Common Stock
< Previous
1
2
3
Next >
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
July 30, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
July 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
June 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
June 10, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
June 06, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
May 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 09, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
March 04, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
February 29, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming March Conferences
February 26, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
February 13, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
January 08, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
December 21, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Inc. (NASDAQ: STTK) Leading the Way in Thursday Trading Based on Percentage Gain
December 14, 2023
Via
Investor Brand Network
Shattuck Labs Inc. (NASDAQ: STTK) is One of Wednesday Morning’s Most Active Stocks
December 13, 2023
Via
Investor Brand Network
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML)
December 13, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation
December 05, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
November 14, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
November 06, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023
November 02, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 10, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
May 25, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 09, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
April 03, 2023
From
Shattuck Labs, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.